Detalhe da pesquisa
1.
Open-label, rapid initiation pilot study for extended-release buprenorphine subcutaneous injection.
Am J Drug Alcohol Abuse
; 49(1): 43-52, 2023 01 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36001871
2.
18-Month efficacy and safety analysis of monthly subcutaneous buprenorphine injection for opioid use disorder: Integrated analysis of phase 3 studies.
J Subst Use Addict Treat
; 154: 209155, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37657559
3.
Continued Posttrial Benefits of Buprenorphine Extended Release: RECOVER Study Findings.
J Addict Med
; 17(2): 182-189, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36111991
4.
Cannabis-Induced Hypodopaminergic Anhedonia and Cognitive Decline in Humans: Embracing Putative Induction of Dopamine Homeostasis.
Front Psychiatry
; 12: 623403, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33868044
5.
Assessment of craving in opioid use disorder: Psychometric evaluation and predictive validity of the opioid craving VAS.
Drug Alcohol Depend
; 229(Pt B): 109057, 2021 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34794061
6.
Transmodulation of Dopaminergic Signaling to Mitigate Hypodopminergia and Pharmaceutical Opioid-Induced Hyperalgesia.
Curr Psychopharmacol
; 9(3): 164-184, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-37361136
7.
In Search of Reward Deficiency Syndrome (RDS)-free Controls: The "Holy Grail" in Genetic Addiction Risk Testing.
Curr Psychopharmacol
; 9(1): 7-21, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32432025
8.
Hypodopaminergia and "Precision Behavioral Management" (PBM): It is a Generational Family Affair.
Curr Pharm Biotechnol
; 21(6): 528-541, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-31820688
9.
The Individualized Treatment of Opioid Use Disorder.
J Manag Care Spec Pharm
; 25(6): 634-636, 2019 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-31134856
10.
Death by Opioids: Are there non-addictive scientific solutions?
J Syst Integr Neurosci
; 52019 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-31824737
11.
Addiction by Any Other Name is Still Addiction: Embracing Molecular Neurogenetic/Epigenetic Basis of Reward Deficiency.
J Addict Sci
; 6(1): 1-4, 2020 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32432229